Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide-induced bladder cancer.

Peter Vlaovic1, Michael A. S. Jewett

  • 1Division of Urology, Department of Surgery, The Toronto Hospital,University of Toronto, Toronto, Ontario.

The Canadian Journal of Urology
|April 5, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Smarter, Not More: The Rationale for Reducing Systematic Cores in the MRI-Targeted Biopsy Era.

The Canadian journal of urology·2026
Same journal

Ten Years of Progress in Advanced Prostate Cancer at the AUA.

The Canadian journal of urology·2026
Same journal

Electroacupuncture for sperm improvement in varicocele: a case report.

The Canadian journal of urology·2026
Same journal

Transperineal approach for penetrating injury of corpus spongiosum and bulbous urethra caused by vesicourethral foreign body: a case report.

The Canadian journal of urology·2026
Same journal

Penile fracture and concomitant severe urethral trauma-a case report and discussion of surgical approach.

The Canadian journal of urology·2026
Same journal

Management of retained bullet fragments from posterior urethra after gunshot wound: a case report.

The Canadian journal of urology·2026
See all related articles

Cyclophosphamide treatment can increase bladder cancer risk. Patients receiving over 20g should have regular urinalysis for up to 11 years post-treatment to detect potential bladder carcinoma.

Area of Science:

  • Oncology
  • Urology
  • Pharmacology

Background:

  • Cyclophosphamide is an alkylating agent used in chemotherapy and immunosuppression.
  • Cyclophosphamide is a known risk factor for secondary malignancies, particularly bladder cancer.
  • The risk of bladder cancer is associated with cumulative dose and duration of cyclophosphamide therapy.

Purpose of the Study:

  • To report cases of cyclophosphamide-induced bladder carcinoma.
  • To review the literature on the risk, mechanisms, and mitigation strategies for cyclophosphamide-induced bladder cancer.
  • To provide recommendations for monitoring patients treated with cyclophosphamide.

Main Methods:

  • Case report of 3 patients with cyclophosphamide-induced bladder carcinoma.
  • Literature review of cyclophosphamide-associated bladder cancer.

Related Experiment Videos

  • Analysis of risk factors, carcinogenic mechanisms, and preventive measures.

    • Main Results:

    • Three cases of bladder carcinoma were identified in patients treated with cyclophosphamide for Wegener's granulomatosis and neuroblastoma.
    • Literature confirms a dose-dependent relationship between cyclophosphamide and bladder cancer risk.
    • Mechanisms involve urothelial damage and DNA adduct formation by cyclophosphamide metabolites.

    Conclusions:

    • Cyclophosphamide should be administered at the lowest effective dose.
    • Patients receiving >20g cumulative dose require routine urinalysis (microscopic hematuria screening) every 3-6 months for up to 11 years post-treatment.
    • Even low pediatric doses (e.g., 600mg) may necessitate lifelong monitoring for bladder cancer risk.